Avinger, Inc. to Present at the Q1 Virtual Investor Summit
Avinger (Nasdaq: AVGR), a medical device company, announced that CFO Mark Weinswig will attend the Q1 Virtual Investor Summit from March 23-25, 2021. Weinswig will present on March 23rd at 4:40 PM ET and will be available for one-on-one meetings. The summit features over 100 companies and 300 investors, focusing on small and micro-cap companies. Avinger specializes in treating Peripheral Artery Disease (PAD), which affects over 12 million people in the U.S.
- None.
- None.
REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire- Avinger, Inc. (Nasdaq: AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that Mark Weinswig, CFO, will be attending the Q1 Virtual Investor Summit. Management will conduct an overview presentation available on the investor relations section of Avinger’s website, www.avinger.com, and be available for one-on-one investor meetings throughout the day.
| Event | Q1 Investor Summit |
| Date | March 23-25th, 2021 |
| Presentation | March 23rd @ 4:40PM ET |
| Location | https://zoom.us/webinar/register/WN_1WnGv7hXQmCjpg7cirqJ_w |
About The Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.
To request complimentary investor registration: please visit our website at www.investorsummitgroup.com
Contact:
Brittney Blocker at brittney@investorsummitgroup.com
Matt Kreps, Managing Director, Darrow Associates Investor Relations, mkreps@darrowir.com, (214) 597-8200
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) crossing catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Follow Avinger on Twitter and Facebook.
Wire Service Contact:
InvestorWire (IW)
Los Angeles, California
212.418.1217 Office
FAQ
When is Avinger presenting at the Q1 Investor Summit?
Who is attending the Q1 Virtual Investor Summit from Avinger?
What is the date range of the Q1 Investor Summit?
Where can I find more information about Avinger's presentation?
What does Avinger specialize in?
